hotspot -WSS

hotspot

author：focus 2025-10-04 04:01:56 - browse：78735

Rachel Haurwitz of Caribou Biosciences — Rachel Haurwitz, CEO of Caribou Biosciences. Elizabeth D. Herman for STAT

Caribou Biosciences said Thursday that its off-the-shelf CAR-T therapy induced durable, complete remissions in patients with advanced B-cell lymphoma that move it closer to the benchmarks set by more established, patient-specific CAR-T therapies.

In an update to an early-stage study, 44% of the 16 patients treated with Caribou’s on-demand therapy, called CB-010, achieved a complete remission lasting a minimum of six months — a key threshold of durability.

The CB-010 result is still preliminary, but it begins to compare favorably to currently approved CAR-T therapies, which must be custom made for each patient and have shown durable remission rates in the range of 36-40%, said Caribou CEO Rachel Haurwitz.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： How to bring more disabled researchers into academia

WSS

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

California wildfire smoke linked to 52,000 early deaths, study says

Deposition: Sackler embraced plan to conceal OxyContin’s strength

Precocious puberty in girls comes with mental health risks

How faith leaders like me can help address America's obesity epidemic

Lilly's Alzheimer's drug donanemab backed by FDA advisers

hotspot

hotspot

explore

Virginia high school admissions case could be legal follow

Report captures long Covid’s disabling effects and policy challenges

Alkermes shareholders re

The Readout: Amylyx, Alumis, and Lundbeck drug updates

Dobbs anniversary: the lost opportunity of abortion as health care

Change Healthcare cyberattack prompts Medicare loan program

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Precocious puberty in girls comes with mental health risks

Trump demands the U.S. pay no more for drugs than other countries … again

How the BIOSECURE Act is already affecting U.S., Chinese life science firms

leisure time

With psoriasis trial ahead, Alumis raises $259 million

RSV shot was 90% effective at preventing hospitalizations in kids

Cheap, fast test for Zika and dengue could cost just $1

ALS patient reclaims some autonomy thanks to wearable 'robot'

California wildfire smoke linked to 52,000 early deaths, study says

'Essentially witchcraft:' A former naturopath takes on the field

focus

explore

hotspot

focus